company background image
A065660 logo

Anterogen.Co.Ltd KOSDAQ:A065660 Stock Report

Last Price

₩15.65k

Market Cap

₩152.3b

7D

-11.8%

1Y

-2.1%

Updated

21 Dec, 2024

Data

Company Financials

Anterogen.Co.,Ltd.

KOSDAQ:A065660 Stock Report

Market Cap: ₩152.3b

A065660 Stock Overview

A bio-venture company, engages in the research, development, and commercialization of cell therapy products using adipose-derived stem cells in South Korea and internationally. More details

A065660 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Anterogen.Co.,Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Anterogen.Co.Ltd
Historical stock prices
Current Share Price₩15,650.00
52 Week High₩19,150.00
52 Week Low₩13,100.00
Beta0.23
1 Month Change-0.76%
3 Month Change8.53%
1 Year Change-2.13%
3 Year Change-72.54%
5 Year Change-61.26%
Change since IPO-59.97%

Recent News & Updates

Does Anterogen.Co.Ltd (KOSDAQ:065660) Have A Healthy Balance Sheet?

Apr 04
Does Anterogen.Co.Ltd (KOSDAQ:065660) Have A Healthy Balance Sheet?

Recent updates

Does Anterogen.Co.Ltd (KOSDAQ:065660) Have A Healthy Balance Sheet?

Apr 04
Does Anterogen.Co.Ltd (KOSDAQ:065660) Have A Healthy Balance Sheet?

Health Check: How Prudently Does Anterogen.Co.Ltd (KOSDAQ:065660) Use Debt?

Feb 05
Health Check: How Prudently Does Anterogen.Co.Ltd (KOSDAQ:065660) Use Debt?

Does Anterogen.Co.Ltd's (KOSDAQ:065660) Share Price Gain of 25% Match Its Business Performance?

Dec 14
Does Anterogen.Co.Ltd's (KOSDAQ:065660) Share Price Gain of 25% Match Its Business Performance?

Shareholder Returns

A065660KR BiotechsKR Market
7D-11.8%-3.9%-3.7%
1Y-2.1%15.6%-10.4%

Return vs Industry: A065660 underperformed the KR Biotechs industry which returned 15.6% over the past year.

Return vs Market: A065660 exceeded the KR Market which returned -10.4% over the past year.

Price Volatility

Is A065660's price volatile compared to industry and market?
A065660 volatility
A065660 Average Weekly Movement6.8%
Biotechs Industry Average Movement8.7%
Market Average Movement6.6%
10% most volatile stocks in KR Market12.7%
10% least volatile stocks in KR Market3.3%

Stable Share Price: A065660 has not had significant price volatility in the past 3 months compared to the KR market.

Volatility Over Time: A065660's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2000n/aSeong-Gu Leeanterogen.com

Anterogen Co.,Ltd., a bio-venture company, engages in the research, development, and commercialization of cell therapy products using adipose-derived stem cells in South Korea and internationally. The company offers medicines, including Cupistem injection, an adipose stem cell product that is used for the treatment of Crohn’s fistula; Queencell, a stromal vascular fraction used for the regeneration of subcutaneous adipose tissue; and Remodulin injection, a medicine for the treatment of pulmonary arterial hypertension.

Anterogen.Co.,Ltd. Fundamentals Summary

How do Anterogen.Co.Ltd's earnings and revenue compare to its market cap?
A065660 fundamental statistics
Market cap₩152.30b
Earnings (TTM)-₩1.44b
Revenue (TTM)₩6.95b

21.9x

P/S Ratio

-105.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A065660 income statement (TTM)
Revenue₩6.95b
Cost of Revenue₩4.21b
Gross Profit₩2.74b
Other Expenses₩4.19b
Earnings-₩1.44b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-148.08
Gross Margin39.47%
Net Profit Margin-20.73%
Debt/Equity Ratio0%

How did A065660 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 04:01
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Anterogen.Co.,Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
JooYong KimKiwoom Securities Co., Ltd.